Pharma

Antibodies.com Supercharges UK Operations with Move to Larger Cambridge HQ

Antibodies.com has moved to a new, five-times-larger headquarters at Cambridge Technopark to support rapid growth and better serve life science researchers worldwide.

Compass Pathways' Phase 3 Psilocybin Readout Raises Efficacy Questions Despite Meeting Primary Endpoint

Investor skepticism underscores challenges in demonstrating robust clinical value in psychedelic therapeutics for depression.

Novo Nordisk Strikes $812 Million Deal with Deep Apple Therapeutics to Strengthen Obesity Pipeline

The Wegovy maker announces strategic agreement worth up to $812 million with Deep Apple Therapeutics, continuing their aggressive investment into its obesity drug pipeline.

Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Receives Marketing Authorization in Australia

Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has been approved in Australia for treating early-stage Alzheimer’s disease in patients with confirmed amyloid pathology.

Breakthrough "Armoured" CAR T-Cell Therapy Shows Promising Results in Tough-to-Treat Lymphomas

In a phase 1 study, 81% of patients responded to IL18-boosted therapy, with over half achieving complete remission.

Women’s Health Therapeutics Market Enters Transformative Growth Phase

BCC Research’s findings underscore a decisive moment for women’s health therapeutics, a sector finally gaining the investment, innovation, and strategic focus it should.